Αποτελέσματα Αναζήτησης
The TOUCH Prescribing Program is designed to: Inform prescribers, infusion center healthcare providers, and patients about the risk of progressive multifocal leukoencephalopathy (PML) associated with TYSABRI including the increased risk of PML with treatment duration and prior immunosuppressant use.
- Touch On-Line
TOUCH On-Line is a web-based tool designed to assist TOUCH...
- How to Enroll
To learn more about enrolling in the TOUCH Prescribing...
- Touch On-Line
Maintain compliance with the TOUCH Prescribing Program. Reduce administrative burden/paperwork for prescribers and infusion sites. Streamline communication to/from prescribers and infusion sites. TOUCH On-Line is accessed with a secure username and password. Click here to start a patient on TYSABRI today.
To learn more about enrolling in the TOUCH Prescribing Program, contact a TYSABRI Support Specialist at Biogen, call toll free: 1-800-456-2255 Monday-Friday, 8:30 AM to 8:00 PM (ET).
TYSABRI is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML).
• TOUCH On-Line is a web-based tool designed to: – Provide real-time access to TYSABRI patient data – Maintain compliance with the TOUCH Prescribing Program
4 Αυγ 2023 · The Tysabri TOUCH Prescribing Program is a restricted program developed by the manufacturer of Tysabri and the US Food and Drug Administration (FDA) intended to educate healthcare professionals and patients on the risks of using Tysabri, including progressive multifocal leukoencephalopathy (PML).
TYSABRI® is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α.
